194 related articles for article (PubMed ID: 11110059)
1. Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Smolnikar K; Löffek S; Schulz T; Michna H; Diel P
Breast Cancer Res Treat; 2000 Oct; 63(3):249-59. PubMed ID: 11110059
[TBL] [Abstract][Full Text] [Related]
2. The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells.
Diel P; Smolnikar K; Michna H
Breast Cancer Res Treat; 1999 Nov; 58(2):87-97. PubMed ID: 10674872
[TBL] [Abstract][Full Text] [Related]
3. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S
Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
6. Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line.
Parisot JP; Leeding KS; Hu XF; DeLuise M; Zalcberg JR; Bach LA
Breast Cancer Res Treat; 1999 Jun; 55(3):231-42. PubMed ID: 10517168
[TBL] [Abstract][Full Text] [Related]
7. interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).
Bouker KB; Skaar TC; Fernandez DR; O'Brien KA; Riggins RB; Cao D; Clarke R
Cancer Res; 2004 Jun; 64(11):4030-9. PubMed ID: 15173018
[TBL] [Abstract][Full Text] [Related]
8. Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells.
Abbas Abidi SM; Howard EW; Dmytryk JJ; Pento JT
Clin Exp Metastasis; 1997 Jul; 15(4):432-9. PubMed ID: 9219732
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
Juncker-Jensen A; Lykkesfeldt AE; Worm J; Ralfkiaer U; Espelund U; Jepsen JS
Growth Horm IGF Res; 2006 Aug; 16(4):224-39. PubMed ID: 16893667
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogens are pro-apoptotic in normal human breast epithelial cells.
Somaï S; Chaouat M; Jacob D; Perrot JY; Rostène W; Forgez P; Gompel A
Int J Cancer; 2003 Jul; 105(5):607-12. PubMed ID: 12740907
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
[TBL] [Abstract][Full Text] [Related]
13. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
Larsen SS; Egeblad M; Jäättelä M; Lykkesfeldt AE
Breast Cancer Res Treat; 1999 Nov; 58(1):41-56. PubMed ID: 10634517
[TBL] [Abstract][Full Text] [Related]
14. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Lykkesfeldt AE; Larsen SS; Briand P
Int J Cancer; 1995 May; 61(4):529-34. PubMed ID: 7759159
[TBL] [Abstract][Full Text] [Related]
15. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
Brockdorff BL; Heiberg I; Lykkesfeldt AE
Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
[TBL] [Abstract][Full Text] [Related]
16. Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7.
Diel P; Olff S; Schmidt S; Michna H
J Steroid Biochem Mol Biol; 2002 Jan; 80(1):61-70. PubMed ID: 11867264
[TBL] [Abstract][Full Text] [Related]
17. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
18. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line.
Ercoli A; Scambia G; Fattorossi A; Raspaglio G; Battaglia A; Cicchillitti L; Malorni W; Rainaldi G; Benedetti Panici P; Mancuso S
Int J Cancer; 1998 Mar; 76(1):47-54. PubMed ID: 9533761
[TBL] [Abstract][Full Text] [Related]
20. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
